Mostrar el registro sencillo del ítem

dc.contributor.authorIzquierdo, Guillermo
dc.contributor.authorGarcía-Agua-Soler, Nuria 
dc.contributor.authorGarcía-Ruiz, Antonio J. 
dc.contributor.authorRus, Macarena
dc.date.accessioned2024-02-09T12:22:31Z
dc.date.available2024-02-09T12:22:31Z
dc.date.issued2015
dc.identifier.citationG. Izquierdo, N. García-Agua Soler, M. Rus, A. J. García-Ruiz, Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies, Brain and Behavior, 2015; 5(6), e00337, doi: 10.1002/brb3.337es_ES
dc.identifier.urihttps://hdl.handle.net/10630/30296
dc.description.abstractObjective: To assess the effectiveness of glatiramer acetate (GA) compared to other multiple sclerosis (MS) therapies in routine clinical practice. Materials and methods: Observational cohort study carried out in MS patients treated with GA (GA cohort) or other MS therapies –switched from GA– (non-GA cohort). Study data were obtained through review of our MS patient database. The primary endpoint was the Expanded Disability Status Scale (EDSS) scores reached at the end of treatment/last check-up. Results: A total of 180 patients were included: GA cohort n = 120, non-GA cohort n = 60. Patients in the GA cohort showed better EDSS scores at the end of treatment/last check-up (mean   SD, 2.8   1.8 vs. 3.9   2.2; P = 0.001) and were 1.65 times more likely to show better EDSS scores compared to the non-GA cohort (odds ratio, 0.606; 95%CI, 0.436–0.843; P = 0.003). Patients in the GA cohort showed longer mean time to reach EDSS scores of 6 (209.1 [95%CI, 187.6–230.6] vs. 164.3 [95%CI, 137.0–191.6] months; P = 0.004) and slower disability progression (hazard ratio, 0.415 [95%CI, 0.286–0.603]; P < 0.001). The annualized relapse rate was lower in the GA cohort (mean   SD, 0.5   0.5 vs. 0.8   0.5; P = 0.001) and patients’ quality of life was improved in this study cohort compared to the non-GA cohort (mean   SD, 0.7   0.1 vs. 0.6   0.2; P = 0.01). Conclusions: GA may slow down the progression of EDSS scores to a greater extent than other MS therapies, as well as achieving a greater reduction in relapses and a greater improvement in patients’ quality of life. Switching from GA to other MS therapies has not proved to entail a better response to treatment.es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectEsclerosis múltiple - Tratamientoes_ES
dc.subject.otherClinical practicees_ES
dc.subject.otherEffectivenesses_ES
dc.subject.otherGlatiramer acetatees_ES
dc.subject.otherMultiple sclerosises_ES
dc.titleEffectiveness of glatiramer acetate compared to other multiple sclerosis therapieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.1002/brb3.337
dc.rights.ccAttribution 4.0 Internacional
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 Internacional